Prasol Chemicals IPO: Date, Price Band, Lot Size, Issue Details and Everything You Need to Know 

Prasol Chemicals is a specialty chemicals manufacturer with more than three decades of operating history. Its portfolio spans acetone-based and phosphorus-based specialty chemicals as well as other differentiated chemistries used across performance chemicals, paints, inks, construction and adhesives, pharmaceuticals, agrochemicals, and home and personal care. The company has built a broad operating footprint around product variety rather than a single chemistry. As of July 15, 2026, the RHP describes a portfolio of more than 150 specialty chemical products, more than 1,600 customers and exports to 69 countries. In FY26, acetone-based products contributed 42.75% of revenue from operations, phosphorus-based products 38.30%, and other specialty chemicals 18.33%. 

Prasol Chemicals IPO is a ₹500 crore offer comprising an ₹80 crore fresh issue and a ₹420 crore offer for sale. That mix is important: 84% of the offer is an OFS and therefore does not bring fresh capital into the company. Of the fresh issue, ₹60 crore is proposed to be used for repayment or pre-payment of certain borrowings, with the balance available for general corporate purposes subject to applicable limits. 

The financial trend has strengthened over the last three reported years, with revenue, operating margins and profit rising. Cash generation, however, has been less linear. That makes both profitability and cash conversion important when assessing the business behind the IPO. 

Prasol Chemicals IPO Dates and Launch Details 

 Prasol Chemicals IPO Price Band and Investment Details 

Prasol Chemicals IPO Structure 

 Since the OFS is substantially larger than the fresh issue, most of the IPO proceeds will go to selling shareholders rather than the company. The balance-sheet impact therefore comes mainly from the ₹80 crore fresh issue, particularly the proposed ₹60 crore debt repayment component. 

About Prasol Chemicals  

Prasol Chemicals was originally incorporated in January 1992. Its business is built around manufacturing specialty chemicals through multiple chemistries rather than selling a narrow set of commodity products. The RHP describes the company as forward integrated in acetone- and phosphorus-based specialty chemicals, alongside a wider range of surfactants, performance additives, ethers, esters, polymers and acids. 

• Product breadth: More than 150 specialty chemical products, with 40 additional products in the development pipeline as of June 30, 2026. Nine of those pipeline products had cleared the pilot stage.
• Customer diversity: The company served 1,618 customers in FY26, compared with 1,586 in FY25 and 1,560 in FY24. Its top 10 customers contributed 23.68% of FY26 revenue.
• Export footprint: Exports contributed 27.29% of FY26 revenue from operations. The company had exported to 69 countries as of July 15, 2026.
• Manufacturing base: Prasol operates facilities at Khopoli and Mahad in Maharashtra. Khopoli utilisation rose to 80.29% in FY26, while Mahad utilisation improved to 44.09% from 25.18% in FY25 and 12.72% in FY24.
• R&D capability: Its in-house R&D team had 37 members as of June 30, 2026, including four PhD holders and 25 chemists. Thirteen new products had been developed and commercialised since April 1, 2023. 

There is also a useful distinction within the revenue mix. Acetone-based chemicals remained the largest category in FY26 at 42.75% of revenue, but their share declined from 46.97% in FY24. Phosphorus-based chemicals increased from 31.82% to 38.30% over the same period. This suggests the growth mix has become somewhat more balanced across the two principal chemistry platforms. 

Prasol Chemicals Financials 

All figures below are in ₹ crore. 

Note: FY24 and FY25 figures are based on Restated Consolidated Financial Information, while FY26 figures are based on Restated Standalone Financial Information. Consolidated financial information was not available for FY26 after Prasol Aromatics Private, the company's erstwhile subsidiary, was struck off in July 2025. 

What do the financials show? 

Revenue from operations increased from ₹876.57 crore in FY24 to ₹1,232.59 crore in FY26. The improvement in profitability was sharper: PAT rose from ₹18.13 crore to ₹83.12 crore. Operating EBITDA margin expanded from 6.91% in FY24 to 8.67% in FY25 and 11.30% in FY26. Adjusted RoCE also improved from 12.61% to 22.43% over the same period. 

The cash-flow trend needs more context. FY24 operating cash flow was unusually strong at ₹115.61 crore, helped by working-capital release, including lower receivables and inventories. In FY25, the direction reversed: higher receivables and inventories absorbed cash, bringing operating cash flow down to ₹22.26 crore and free cash flow slightly negative at about ₹0.30 crore. FY26 saw operating cash flow recover to ₹49.47 crore and free cash flow improve to ₹10.86 crore after PPE purchases and disposal proceeds. 

This distinction matters because the profit line has improved faster than cash generation. Investors therefore need to watch whether the stronger FY26 earnings can translate into consistently higher operating cash flow as the business expands. 

Borrowings and the use of fresh proceeds 

Balance sheet borrowings were ₹110.06 crore as of March 31, 2026, comprising ₹47.00 crore of non-current borrowings and ₹63.06 crore of current borrowings. This compares with ₹101.05 crore in FY25 and ₹82.07 crore in FY24. Lease liabilities are not included in these borrowings figures. 

Prasol proposes to deploy ₹60 crore from the fresh issue towards repayment or pre-payment of certain borrowings. If executed as proposed, this would reduce a meaningful portion of the balance-sheet debt base. The company will not receive any proceeds from the ₹420 crore OFS. 

Sector and Market Context 

The RHP’s industry report estimates India’s specialty chemicals market at ₹5,563 billion in FY26, up from ₹2,240 billion in FY19, and projects it to reach ₹7,541 billion by FY29. The report expects a 10% to 12% CAGR over the next four years, supported by domestic demand, exports, import substitution, supply chain diversification and continued investment in R&D and capacity. 

For Prasol, that backdrop matters because its products feed several downstream industries rather than one end market. But specialty chemicals also remain exposed to raw-material availability and pricing, environmental compliance, customer qualification cycles and the economics of new capacity. Growth in the sector does not automatically translate into the same growth or margins for every manufacturer. 

Key Considerations for Investors 

Strengths 

• Diversified chemistry and application base: Revenue is spread across acetone-based, phosphorus-based and other specialty products serving multiple end-use industries.
• Improving profitability: Operating EBITDA margin rose from 6.91% in FY24 to 11.30% in FY26, while PAT margin improved from 2.07% to 6.74%.
• Broad customer and export reach: The company served more than 1,600 customers and had exports to 69 countries as of July 15, 2026.
• Product-development pipeline: Forty products were under development as of June 30, 2026, providing a potential route to broaden the portfolio further. 

Risks 

• Raw material dependence: Imports accounted for 65.96% of the cost of materials procured in FY26, while the top 10 suppliers represented 68.87% of raw-material consumption. Supply disruptions or price volatility can therefore affect margins and production.
• Manufacturing and environmental risk: The Mahad facility was shut from October 27, 2023 to May 3, 2024 following a gas-leak incident and regulatory closure directions. The facility has since resumed operations, but manufacturing safety and environmental compliance remain material risks.
• Mahad is still not fully stabilised financially: The facility’s loss before exceptional items and tax narrowed to ₹12.17 crore in FY26 from ₹15.77 crore in FY25 and ₹22.77 crore in FY24, but it remained loss-making.
• Cash conversion has been uneven: Operating cash flow fell sharply in FY25 as working capital absorbed cash, before recovering in FY26. Sustained growth will need to be matched by disciplined working-capital management.
• Export exposure: More than a quarter of FY26 revenue came from exports, creating exposure to currency movements, overseas demand and regulatory or geopolitical changes across markets. 

Opportunities 

• Higher utilisation at existing facilities: Khopoli reached 80.29% utilisation in FY26, while Mahad has been ramping up from a low base. Better utilisation can help spread fixed costs if demand keeps pace.
• Product mix expansion: The 40-product development pipeline and recent commercialisation of new products can deepen relationships with existing customers and open additional applications.
• Sector growth and import substitution: The prospectus industry report expects continued expansion in Indian specialty chemicals, supported in part by supply-chain diversification and domestic substitution opportunities. 

Conclusion 

Prasol Chemicals enters the IPO market with a business that has become larger and more profitable over the last three reported years. Its portfolio breadth, customer base, export reach and improving operating margins provide one side of the story. The other side is the need to sustain cash conversion, manage raw-material dependence, continue the stabilisation of Mahad and execute future product and capacity expansion without weakening returns. 

The IPO itself is predominantly an OFS, with only ₹80 crore of the ₹500 crore offer coming into the company. The proposed ₹60 crore debt repayment gives the fresh issue a clear balance-sheet purpose, but investors should separately assess the business fundamentals and the valuation implied by the final offer price. The final view should depend on the offer valuation, financial trajectory, cash-flow strength, operating risks and the investor’s own suitability.

Disclaimer: This article is for educational purposes only. It is not investment advice or a recommendation to apply for the IPO.